Author

Shafic Makumbi

Observed name: S Makumbi

Observed institutions: University of Padua, Mbarara University of Science and Technology, Radboud University Nijmegen, University of Zimbabwe, Radboud University Medical Center, Research Institute Hospital 12 de Octubre, MRC Clinical Trials Unit at UCL, Hospital Universitario 12 De Octubre, Baylor College of Medicine Children’s Foundation, Infectious Diseases Research Collaboration, Joint Clinical Research Centre, Radboud Institute for Health Sciences, University College London, Medical Research Council

ORCID: 0009-0009-2284-9017

Observed ORCID: 0009-0009-2284-9017

OpenAlex ID: A5038416217

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial

2022 · Nicholas I Paton, Joseph Musaazi, et al. · The Lancet HIV · 138

PDF

Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial

2020 · Pauline D J Bollen, Cecilia L Moore, et al. · The Lancet HIV · 47

PDF

Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

2022 · Hylke Waalewijn, Man K Chan, et al. · The Lancet HIV · 40

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

2022 · Pauline Amuge, Abbas Lugemwa, et al. · The Lancet HIV · 36

PDF

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

2022 · Anna Turkova, Hylke Waalewijn, et al. · The Lancet HIV · 24

PDF

Second-Line Antiretroviral Therapy for Children Living with HIV in Africa

2025 · Victor Musiime, Mutsa Bwakura-Dangarembizi, et al. · New England Journal of Medicine · 20

First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial

2023 · Hylke Waalewijn, Alexander J Szubert, et al. · Clinical Infectious Diseases · 15

PDF

Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

2023 · Anna Turkova, Ellen White, et al. · The Lancet Child & Adolescent Health · 14

PDF

Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial

2023 · Lisanne A H Bevers, Hylke Waalewijn, et al. · Clinical Infectious Diseases · 10

PDF

Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial

2026 · Anna Turkova, Ellen White, et al. · The Lancet Child & Adolescent Health · 3

Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV

2025 · Lufina Tsirizani, Hylke Waalewijn, et al. · Antimicrobial Agents and Chemotherapy · 2

Brief Report: Pharmacokinetic Data of Atazanavir/Ritonavir in Second-Line Treatment of Children Living With HIV

2025 · Anne E. M. Kamphuis, Hylke Waalewijn, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2

Influence of age and co‐medication on dolutegravir glucuronidation in paediatric patients

2024 · Tom G. Jacobs, Hylke Waalewijn, et al. · British Journal of Clinical Pharmacology · 2

PDF

Population Pharmacokinetics of Dolutegravir in African Children: Results From the CHAPAS-4 Trial

2024 · Hylke Waalewijn, Roeland E Wasmann, et al. · Journal of the Pediatric Infectious Diseases Society · 2

PDF

OA-225 Optimising second line anchor drug options for children with HIV in Africa: 96 week results of the CHAPAS-4 randomised trial

2023 · Abbas Lugemwa, Alexander J Szubert, et al. · BMJ Global Health · 1

PDF

Pharmacokinetics of lopinavir/ritonavir in second-line treatment of children with HIV in the CHAPAS-4 trial

2025 · Anne E.M. Kamphuis, Timo Kiezebrink, et al. · AIDS

Voluntariness of consent in paediatric HIV clinical trials: a mixed-methods, cross-sectional study of participants in the CHAPAS-4 and ODYSSEY trials in Uganda

2024 · Shafic Makumbi, Francis Bajunirwe, et al. · BMJ Open

PDF

NP-003 Steady-state pharmacokinetics and early safety data in HIV-infected african children weighing ≥25 kg after switching to 50 mg film-coated dolutegravir tablets in the ODYSSEY trial

2020 · PDJ Bollen, A Turkova, et al. · European Journal of Hospital Pharmacy

PDF

Works count: 18

Citation count: 356

H-index: 9

I10-index: 9